drugset / Trial / NCT05204927
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
RandomizedCrossoverOpen-labelTreatment
Summary
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2024-08-02
- Completion
- 2029-02
Outcome
Met primary endpoint
release “its ECLIPSE trial met its primary endpoint.” curiumpharma.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-PSMA-I&T | Other / unclassified | 7400 mbq | — |
| Comparator | Abiraterone acetate | Small molecule | — | — |
| Comparator | Enzalutamide | Other / unclassified | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |